Study of Tapering and Discontinuing Biological DMARDs in Rheumatoid Arthritis Patients
NCT04472390 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2020-07-15
Summary
This study aims to analyses time to disease relapse of RA patients if TNF-α inhibitors are being tapered, the predictive factors that are associated with successful taper of TNF-α inhibitors. Also, investigate the effects associated with dose tapering of TNF-α inhibitors.
Conditions
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Principal Investigators
-
Yen-Hui Chen · NTU Clinical Pharmacy School
Eligibility
- Min Age
- 20 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-12-03
- Primary Completion
- 2021-12-31
- Completion
- 2021-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis
NCT01602302 ·Status: TERMINATED ·Phase: PHASE4
-
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
NCT01578850 ·Status: COMPLETED ·Phase: PHASE4
-
Takayasu Arteritis Clinical Trial in China
NCT02981979 ·Status: COMPLETED ·Phase: NA
-
Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients
NCT04485325 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing Etanercept With Usual DMARD Therapy in Subjects With Rheumatoid Arthritis in the Asia Pacific Region
NCT00422227 ·Status: COMPLETED ·Phase: PHASE4
-
Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents
NCT01691014 ·Status: TERMINATED
-
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
NCT05246280 ·Status: TERMINATED ·Phase: PHASE3
-
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
NCT00796705 ·Status: TERMINATED ·Phase: PHASE4
-
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment
NCT00902005 ·Status: COMPLETED
-
Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis
NCT00432406 ·Status: COMPLETED ·Phase: PHASE4
-
Role of Chemokines and Proinflammatory Cytokines in Rheumatoid Synovial Pathological Changes
NCT00845949 ·Status: WITHDRAWN
-
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
NCT01692899 ·Status: COMPLETED
-
Scintigraphy for Prediction In Rheumatoid Intentional Therapy Tapering
NCT05983848 ·Status: NOT_YET_RECRUITING
-
Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA
NCT04078191 ·Status: TERMINATED ·Phase: PHASE2
-
Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA
NCT00858780 ·Status: COMPLETED ·Phase: PHASE4
-
Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants
NCT01009879 ·Status: WITHDRAWN ·Phase: PHASE4
-
Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study
NCT01659242 ·Status: TERMINATED ·Phase: PHASE4
-
Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)
NCT00115219 ·Status: COMPLETED ·Phase: PHASE4
-
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
NCT01981473 ·Status: COMPLETED
-
Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis
NCT00443950 ·Status: COMPLETED ·Phase: PHASE3
-
Genetic and Immune Studies of Rheumatoid Arthritis and Related Conditions
NCT00001291 ·Status: COMPLETED
-
Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)
NCT02094326 ·Status: COMPLETED
-
Arthroscopic Synovectomy Combined With DMARDs in the Treatment of Refractory Elbow Rheumatoid Arthritis
NCT04454034 ·Status: UNKNOWN
-
A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis
NCT00484237 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis
NCT00445770 ·Status: COMPLETED ·Phase: PHASE3